Poster session 2
Vaccines

Programm

• • Poster Presentation
  • PP 251

  Antibody titres following vaccination by Chadox-1 nCOV-19 vaccine in cancer patients – experience at a tertiary cancer care center

  • Dr. Preeti Chavan (Navi Mumbai / IN)

   SARS -CoV2 and other coronaviruses, Vaccines
• • Poster Presentation
  • PP 252

  Memory T-cell responses with a Th17 signature in solid tumour patients with previous SARS-CoV-2 infection followed by BNT162b2 vaccination

  • Miriam Echaide (Pamplona / ES)

   Vaccines
• • Poster Presentation
  • PP 253

  Molecular evolution of Dengue virus 3 in Senegal between 2009 to 2022 – implications on prevention and therapeutic counter-measures

  • Idrissa Dieng (Dakar / SN)

   Antivirals, Vaccines
• • Poster Presentation
  • PP 254

  Novel genetically engineered influenza A virus derived defective interfering particles for antiviral treatment and vaccination

  • Tanya Dogra (Magdeburg / DE)

   Vaccines
• • Poster Presentation
  • PP 255

  Profiling of coronavirus-derived B-cell epitopes and validation of vaccination-induced antibody responses with PEPperCHIP® peptide microarrays and a bead-based multiplex assay

  • Dr. Thorsten Zacher (Heidelberg / DE)

   Immune response to virus infection, Vaccines
• • Poster Presentation
  • PP 256

  Cellular proteins that bind to the RNA of flaviviruses attenuated by unnatural dinucleotide frequencies

  • Joyce van Bree (Wageningen / NL)

   Vaccines
• • Poster Presentation
  • PP 257

  Development of robust primary human respiratory epithelial infection models for respiratory syncytial virus and influenza A virus to support vaccine research

  • Rosanne Koutstaal (Bilthoven / NL)

   Vaccines
• • Poster Presentation
  • PP 258

  Characterization and expression of domains of Alphaherpesvirus bovine 1/5 envelope glycoproteins B in Komagataella phaffi

  • Dr. Juan Sebastian Quintero Barbosa (Bogota / CO)

   Vaccines
• • Poster Presentation
  • PP 259

  Envelope protein domain III is a key determinate of Yellow Fever Virus structure

  • Summa Bibby (St Lucia / AU)

   Immune response to virus infection, Vaccines
• • Poster Presentation
  • PP 260

  Characterizing neutralization profiles after bivalent COVID-19 boosting using antigenic cartography

  • Annika Rössler (Innsbruck / AT)

   Vaccines
• • Poster Presentation
  • PP 262

  Reduced transcription of the mutated genomic segment 7 of the novel "OP7" influenza defective interfering particle intended for use as an antiviral

  • Dr. Julita Piasecka (Magdeburg / DE)

   Vaccines
• • Poster Presentation
  • PP 263

  High-throughput identification of immunogenic B and T cell epitopes meets deep immune cell phenotyping

  • Dr. Thorsten Zacher (Heidelberg / DE)

   Vaccines
• • Poster Presentation
  • PP 264

  T cell responses following COVID-19 vaccination in primary immunodeficiency patients

  • Pinja Jalkanen (Turku / FI)

   Vaccines
• • Poster Presentation
  • PP 265

  Neutralizing Influenza A H1N1 using functionalized DNA-origami nanoshells

  • Michael Schachtner (Regensburg / DE)

   Vaccines
• • Poster Presentation
  • PP 266

  Multiplex serology to differentiate pan-hepatitis virus-specific antibody responses in vaccinated and infected individuals

  • Dr. Tanja Michel (Reutlingen / DE)

   Vaccines
• • Poster Presentation
  • PP 267

  Detection and characterization of the replication cycle of the Israel Turkey Meningoencephalitis virus

  • Dr. Leah Baraz (Jerusalem / IL)

   Vaccines
• • Poster Presentation
  • PP 269

  Impaired humoral but normal cellular immune response in individuals with chronic lymphocytic leukaemia who received the complete vaccination schedule against SARS-CoV-2

  • Clara Sánchez-Menéndez (Majadahonda / ES)
  • Montserrat Torres (Majadahonda / ES)

   Vaccines
• • Poster Presentation
  • PP 270

  Sensitive localization of viral RNA in cells by direct RNA padlock probing and in-situ sequencing

  • Shazeb Ahmad (Wuerzburg / DE)

   Vaccines
• • Poster Presentation
  • PP 271

  Genetic analyses-based glycoprotein design of Nipah Virus (NiV) vaccines in Bangladesh, Malaysia, Cambodia and India

  • Dr. In-Ohk Ouh (Cheongju-Si / KR)

   Vaccines
• • Poster Presentation
  • PP 272

  Genetic diversity-based design of Nipah virus Fusion protein vaccines candidate sequences in Malaysia, Bangladesh, Cambodia, Thiland and India

  • Dr. Lim Heeji (Cheongju-si / KR)
  • Moon Seoyoung (Cheongju-si / KR)
  • Dr. Yim Minsu (Cheongju-si / KR)
  • Choi Kyounghwa (Cheongju-si / KR)
  • Dr. In Hyunju (Cheongju-si / KR)

   Vaccines
• • Poster Presentation
  • PP 273

  Lab adapted vs contemporary RSVs: single amino acid changes modulate F protein mediated cell fusion

  • Sophie M. Kolbe (Hannover / DE)

   Vaccines
• • Poster Presentation
  • PP 274

  A profile of HIV-1 anti-viral antibody features in a large well-characterized cohort of people living with HIV-1 for improved antibody-based therapy and cure strategies

  • Marloes Grobben (Amsterdam / NL)

   Vaccines
• • Poster Presentation
  • PP 275

  Duck pluripotent stem cells replicate efficiently influenza viruses

  • Dr. Sylvie Rival-Gervier (Bron / FR)

   Vaccines
• • Poster Presentation
  • PP 276

  Establishment and characterization of a viral vector vaccine candidate for reproduction control of pigs

  • Dr. Jihye Shin (Gimcheon-si / KR)

   Vaccines
• • Poster Presentation
  • PP 277

  A safety and immunogenicity of novel live bivalent porcine diarrhea viruses vaccine in pigs

  • Dr. Gyu-Nam Park (Gimcheon-si / KR)

   Vaccines, Veterinary virology
• • Poster Presentation
  • PP 278

  Early immune signature as correlate of protective antibody response to the BNT162b2 mRNA vaccine

  • Dr. Alessandro Sinigaglia (Padova / IT)

   SARS -CoV2 and other coronaviruses, Vaccines
• • Poster Presentation
  • PP 279

  Nucleoside-modified mRNA vaccines protect IFNAR^–/– mice against Crimean-Congo hemorrhagic fever virus infection

  • Dr. Sofia Appelberg (Stockholm / SE)

   Immune response to virus infection, Vaccines
• • Poster Presentation
  • PP 280

  Human endogenous retrovirus-enveloped baculoviral DNA vaccines against SARS-CoV2 variants

  • Dr. Young Bong Kim (Seoul / KR)

   Vaccines, Viral vectors
• • Poster Presentation
  • PP 281

  Virus-like particle – mediated delivery of the RIG-I agonist M8 triggers a robust prophylactic and therapeutic antiviral activity

  • Dr. Enrico Palermo (Rome / IT)

   Immune response to virus infection, Vaccines
• • Poster Presentation
  • PP 282

  Performance of the twist biosciences respiratory virus research panel versus BioFire FilmArray respiratory 2.1 panel in the identification of respiratory viruses in simulated and clinical samples

  • Elizabeth Kalimeris (Oxford / GB)

   Vaccines
• • Poster Presentation
  • PP 283

  Combined DNA vaccination with chimeric HBV-HCV virus-like particles and NS3/4A protease or NS5B polymerase induces a potent humoral and cellular responses against HCV

  • Katarzyna Grzyb (Gdansk / PL)

   Immune response to virus infection, Vaccines
• • Poster Presentation
  • PP 284

  Analysis if elevated high seroprevalence of anti-TBEV IgG among hunters in Poland is related to vaccination or to exposure to TBEV infection among people belonging to high risk group

  • Agnieszka Kołakowska-Kulesza (Warsaw / PL)

   One Health, Vaccines